Atlas Trials

Pegylated Liposomal Doxorubicin, PD-1 in Treating Muscle Invasive Bladder Cancer

Clinical trial NCT04101812 · UNKNOWN

Trial details

NCT number
NCT04101812
Sponsor
Tianjin Medical University Second Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Muscle Invasive Bladder Cancer
Start date
2019-09-17
Primary completion
2020-05-31
Enrollment
60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.